|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endogenous Cushing syndrome (CS) in pediatrics is rare; it may be caused by tumors that produce corticotropin in the pituitary gland or elsewhere, tumors that produce corticotropin-releasing hormone anywhere, and adrenocortical masses that produce cortisol.
|
27241967 |
2016 |
|
Cushing Syndrome
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Ectopic cushing's syndrome due to corticotropin releasing hormone.
|
31041631 |
2019 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings indicate that chronic production of excess CRF results in sustained stimulation of pituitary corticotrope cells, resulting in elevated ACTH and consequent glucocorticoid overproduction, a condition that leads to the development of Cushing's syndrome.
|
1597149 |
1992 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
MGD |
ACTH secretion is stimulated by CRH, and we report a mouse model for Cushing's syndrome due to an N-ethyl-N-nitrosourea (ENU) induced Crh mutation at -120 bp of the promoter region, which significantly increased luciferase reporter activity and was thus a gain-of-function mutation.
|
24302625 |
2014 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, the finding of polyclonality in hyperplastic corticotroph tissue from a patient with an ectopic CRH-secreting tumor suggests there may be a more direct role for CRH in the pathogenesis of Cushing's syndrome in rare cases.
|
7805653 |
1994 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort study, including children who underwent surgery due to CS (n = 115), was divided into children with a pituitary adenoma (Cushing disease) (n = 88), primary adrenal CS (n = 21), or ectopic adrenocorticotropin- or corticotropin-releasing hormone (ACTH-/CRH)-secreting tumors (n = 6).
|
28433999 |
2017 |
|
Cushing Syndrome
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined whether this relative hypercortisolism is associated with alterations in the pituitary-adrenocortical response to evening corticotropin-releasing hormone (CRH) stimulation.
|
28444400 |
2017 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACTH = adrenocorticotropic hormone; BIPSS = bilateral inferior petrosal sinus sampling; CBG = corticosteroid-binding globulin; CD = Cushing disease; CRH = corticotropin-releasing hormone; CS = Cushing syndrome; Dex = dexamethasone; DST = dexamethasone suppression test; EAS = ectopic ACTH syndrome; FDA = U.S. Food & Drug Administration; HDDST = high-dose DST; IPS/P = inferior petrosal sinus to peripheral; MRI = magnetic resonance imaging; NET = neuroendocrine tumor; PET = positron emission tomography; UFC = urinary free cortisol.
|
28614036 |
2017 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
CTD_human |
We investigated whether the blockade of CRF receptors influences the development of hair loss in CRF over-expressing (OE)-mice that display phenotypes of Cushing's syndrome and chronic stress, including alopecia.
|
21359208 |
2011 |
|
Cushing Syndrome
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hormonal challenge tests, such as the dexamethasone/corticotropin-releasing hormone test, have revealed elevated HPA activity (hypercortisolism) in at least a portion of patients with depression, although growing evidence has suggested that abnormally low HPA axis (hypocortisolism) has also been implicated in a variety of stress-related conditions.
|
20923424 |
2010 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thymic NET with CS exhibited stronger immunoreactivity for ACTH and CRH than those without CS.
|
30502716 |
2019 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACTH = adrenocorticotropic hormone AUC = area under the curve CRH = corticotropin-releasing hormone CS = Cushing syndrome ECLIA = electrochemiluminescence immuno-assay LDDST = low-dose dexamethasone suppression test LNPC = late-night plasma cortisol LNSC = late-night salivary cortisol ONDST = overnight dexamethasone suppression test RIA = radio-immuno assay UFC = urinary free cortisol.
|
29144801 |
2018 |
|
Cushing Syndrome
|
0.600 |
Biomarker
|
disease |
BEFREE |
To characterize somatostatin receptor status in vivo and ex vivo and immunoreactivity and gene transcription for proopiomelanocortin (POMC) and corticotropin-releasing hormone (CRH) in a case of Cushing's syndrome caused by a sporadic metastatic medullary thyroid carcinoma (MTC).
|
12053094 |
2002 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because both cortisol and CRH have behavioral effects, and hypothalamic CRH hypersecretion has been associated with chronic states of anxiety and depression, we performed endocrine and psychologic studies in consecutively admitted parents of patients with classic congenital adrenal hyperplasia due to 21-OH deficiency and parents of children with other chronic endocrine disorders.
|
15126546 |
2004 |
|
Mental Depression
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Variation in the corticotropin-releasing hormone receptor (CRHR1) gene has been shown to interact with early life stress to predict adult depression.
|
19596121 |
2009 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Preclinical studies have shown that dysregulation of the corticotropin releasing factor (CRF) neurotransmission has been implicated in stress-related psychopathologies such as depression and anxiety, and may affect alcohol consumption.
|
29118713 |
2017 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Abnormalities in CRH secretion have been documented in both the depression and manic phases of bipolar disorder (BPD).
|
9399692 |
1998 |
|
Mental Depression
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of glucocorticoid and type 1 corticotropin-releasing hormone receptors gene variants and risk for depression during pregnancy and post-partum.
|
23726670 |
2013 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serotonin, norepinephrine, dopamine, and trace amines, such as the "endogenous amphetamine" phenylethylamine, are increased in brain, which leads to changes in neuroplasticity by e.g. increased neurotrophic growth factors and translates to reduced stress-induced hypersecretion of corticotropin releasing factor (CRF) and positive testing in animal studies of depression.
|
28655495 |
2017 |
|
Mental Depression
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Early-life adversity, such as physical or sexual abuse during childhood, results in long-lasting changes in the CRF-mediated stress response and a greatly increased risk of depression in genetically predisposed persons.
|
16124836 |
2005 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
A concatenation of findings from preclinical and clinical studies support a preeminent function for the corticotropin-releasing factor (CRF) system in mediating the physiological response to external stressors and in the pathophysiology of anxiety and depression.
|
20010888 |
2010 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
The corticotropin releasing hormone (CRH) and the CRH receptor 1 (CRHR1) have been implicated in the link between early life adversity and adult anxiety and depression, with rodent studies identifying the very early postnatal period as highly susceptible to this programming.
|
24630468 |
2014 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study we investigate whether the two forms of dendritic cell nuclear protein-1 might act on corticotropin-releasing hormone, which plays a crucial role in the stress response and in the pathogenesis of depression.
|
20693543 |
2010 |
|
Mental Depression
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that RAR-alpha might contribute to regulating the activity of CRH neurons in vivo, and the vulnerable character of the critical proteins in RA signaling pathways might provide novel targets for therapeutic strategies for depression.
|
19596122 |
2009 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gross anatomical abnormalities (volume changes of the third ventricle, the hypothalamus, and its nuclei) and alterations at the cellular level (loss of neurons, increased or decreased expression of hypothalamic peptides such as oxytocin, vasopressin, corticotropin-releasing hormone, and other regulatory factors as well as of enzymes involved in neurotransmitter and neuropeptide metabolism) have been reported in schizophrenia and/or depression.
|
29767278 |
2019 |